Form 4: Olema Pharma COO/CFO Sells Over 100K Shares
Insider Transaction Report
Olema Pharmaceuticals' Chief Operating and Financial Officer, Shane Kovacs, reported two sales of common stock totaling 103,822 shares in January 2026.
Summary
- Shane William Charles Kovacs, the Chief Operating and Financial Officer of Olema Pharmaceuticals, Inc. (OLMA), reported two transactions involving the sale of common stock.
- On January 13, 2026, Kovacs sold 3,822 shares of Olema Pharmaceuticals common stock at a weighted average price of $28.01 per share, with prices ranging from $28.00 to $28.03.
- On January 15, 2026, an additional 100,000 shares of common stock were sold at a weighted average price of $28.73 per share, with prices ranging from $28.50 to $29.18.
- These transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
- Following these reported sales, Kovacs directly beneficially owns 139,727 shares of Olema Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The filing is a standard Form 4 reporting an insider stock sale, which is a factual disclosure. The transaction was made under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily indicative of new information, thus maintaining a neutral sentiment.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing reports an insider stock transaction, which is a routine disclosure for publicly traded companies. It does not provide information directly related to broader industry trends or competitive landscape, but rather details a specific officer's equity activity.
Stakeholder Impact
- Shareholders: May interpret the insider sale as a signal, although the disclosure that the transactions were made pursuant to a Rule 10b5-1 plan suggests they were pre-planned liquidity events rather than a reaction to new, non-public information.
Key Dates
| Date | Description |
|---|---|
| 01/13/2026 | Sale of 3,822 shares of common stock by Shane Kovacs. |
| 01/15/2026 | Sale of 100,000 shares of common stock by Shane Kovacs. |
Keywords
Olema Pharmaceuticals, OLMA, Form 4, insider trading, stock sale, Shane Kovacs, officer, COO, CFO, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.